Montoro-Jiménez Irene, Granda-Díaz Rocío, Menéndez Sofía T, Prieto-Fernández Llara, Otero-Rosales María, Álvarez-González Miguel, García-de-la-Fuente Vanessa, Rodríguez Aida, Rodrigo Juan P, Álvarez-Teijeiro Saúl, García-Pedrero Juana M, Hermida-Prado Francisco
Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, 33011 Oviedo, Spain.
CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Int J Mol Sci. 2024 Feb 26;25(5):2695. doi: 10.3390/ijms25052695.
The and genes map at 3q26, a chromosomal region frequently amplified in head and neck cancers, which is associated with poor prognosis. This study explores the clinical significance of and gene amplification in early tumorigenesis. Gene copy number was analyzed by real-time PCR in 62 laryngeal precancerous lesions and correlated with histopathological grading and laryngeal cancer risk. Amplification of the and genes was frequently detected in 19 (31%) and 32 (52%) laryngeal dysplasias, respectively, and co-amplification in 18 (29%) cases. The and amplifications were predominant in high-grade dysplasias and significantly associated with laryngeal cancer risk beyond histological criteria. Multivariable Cox analysis further revealed gene amplification as an independent predictor of laryngeal cancer development. Interestingly, combined and amplification allowed us to distinguish three cancer risk subgroups, and and co-amplification was found the strongest predictor by ROC analysis. Our data demonstrate the clinical relevance of and amplification in early laryngeal tumorigenesis. Remarkably, amplification was found to be an independent cancer predictor. Furthermore, combined and amplification is emerging as a valuable and easy-to-implement tool for cancer risk assessment in patients with laryngeal precancerous lesions beyond current WHO histological grading.
[基因名称1]和[基因名称2]基因定位于3q26，这是一个在头颈癌中经常发生扩增的染色体区域，与预后不良相关。本研究探讨了[基因名称1]和[基因名称2]基因扩增在早期肿瘤发生中的临床意义。通过实时PCR分析了62例喉癌前病变中的基因拷贝数，并与组织病理学分级和喉癌风险相关联。[基因名称1]和[基因名称2]基因的扩增分别在19例（31%）和32例（52%）喉发育异常中频繁检测到，18例（29%）为共扩增。[基因名称1]和[基因名称2]的扩增在高级别发育异常中占主导地位，并且在组织学标准之外与喉癌风险显著相关。多变量Cox分析进一步显示[基因名称1]基因扩增是喉癌发生的独立预测因子。有趣的是，[基因名称1]和[基因名称2]联合扩增使我们能够区分三个癌症风险亚组，并且通过ROC分析发现[基因名称1]和[基因名称2]共扩增是最强的预测因子。我们的数据证明了[基因名称1]和[基因名称2]扩增在早期喉肿瘤发生中的临床相关性。值得注意的是，[基因名称1]扩增被发现是一个独立的癌症预测因子。此外，[基因名称1]和[基因名称2]联合扩增正在成为一种有价值且易于实施的工具，用于评估喉癌前病变患者超出当前WHO组织学分级的癌症风险。
